Showing results (231-240 of 259) with videos related to
Sort By:
Pageof 26
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2023
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset AnalysisRoss A Soo, Byoung Chul Cho, Joo-Hang Kim, et al.Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2023
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung CancerPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Pageof 26